How many clinical trials are there for Recurrent Hepatoblastoma?

PlainTrial tracks 10 US clinical trials for Recurrent Hepatoblastoma, of which 2 are currently recruiting.

Which interventions appear most often on Recurrent Hepatoblastoma trial records?

Computed Tomography is the most-linked intervention name on Recurrent Hepatoblastoma records (4 trial links), followed by Biospecimen Collection. Names are sponsor-reported on ClinicalTrials.gov.

How do I find a recruiting trial for Recurrent Hepatoblastoma?

Use the trial list filtered by Recruiting status, or visit the trial finder to search by condition and state. Always discuss with your healthcare provider.

Is this data current?

Data is from ClinicalTrials.gov. Trial status may have changed. Always verify at ClinicalTrials.gov before making participation decisions.

Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Recurrent Hepatoblastoma: early-phase trial registry

Compiled by PlainTrial · August 8, 2026

2 of 10 indexed Recurrent Hepatoblastoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

10 US clinical trials · 2 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Recurrent Hepatoblastoma: 10 US clinical trials tracked, 2 recruiting.

Recurrent Hepatoblastoma is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 8 of these trials.

Enrollment posture brief

Registry condition recurrent-hepatoblastoma

Volume-matched condition peers

Nearest open-share peer: Acral Lentiginous Melanoma (20% recruiting · 5 trials)

Open-enrollment share among volume-matched conditions near Recurrent Hepatoblastoma

Recurrent Hepatoblastoma lists 2 open slots (20% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Hepatoblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

Recurrent Hepatoblastoma is recruiting below its size-band peers.

2 of 10 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
One sponsor concentrates Recurrent Hepatoblastoma research.

National Cancer Institute (NCI) accounts for 8 of 10 trials (80%). 3 distinct sponsors appear on at least one study for this condition label.
Most Recurrent Hepatoblastoma trials plan to enrol fewer than 100 people.

Median target enrolment is 20 among the 10 trials that report a genuine target (sentinel values excluded). 9 of those (90%) plan for fewer than 100 participants.
Recurrent Hepatoblastoma research is mostly interventional.

10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 1 147 participants

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

NCT04851119

RECRUITING Phase 1 90 participants

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

St. Jude Children's Research Hospital

NCT04901702

ACTIVE NOT RECRUITING Phase 2 20 participants